GlassScriptPhysician profile
German Laufer
NPI 1952526816
$866.38
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $701 · 2020: $149 · 2021: $16.24.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acorda Therapeutics, INC | $220.73 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $109.16 | 2019 | |
| Amgen INC. | $101.16 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $80.41 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $72.36 | 2019-2020 | |
| Lilly USA, LLC | $45.57 | 2019 | |
| Lundbeck LLC | $43.90 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $35.82 | 2020 | |
| Ge Healthcare | $31.70 | 2019-2020 | |
| Kyowa Kirin, INC. | $29.91 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $22.22 | 2020 | |
| Novartis Pharmaceuticals Corporation | $21.43 | 2019 | |
| Owp Pharmaceuticals, INC. | $17.78 | 2019 | |
| Arbor Pharmaceuticals, INC. | $17.60 | 2019 | |
| Allergan, INC. | $16.63 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw German Laufer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.